Tags

Type your tag names separated by a space and hit enter

Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure.
Expert Opin Investig Drugs. 2000 May; 9(5):963-73.EO

Abstract

There are several reasons to believe that agents that augment cAMP-mediated signalling in cardiac myocytes should have beneficial effects in patients with heart failure. However, clinical trials of first-generation cyclic nucleotide phosphodiesterase (PDE3) inhibitors, which raise cAMP content by blocking its hydrolysis, have shown that chronic administration of these drugs affect survival adversely. The problem may be the non-selective activation of a broad spectrum of cAMP-regulated cellular responses these agents elicit. More selective (or alternatively selective) cyclic nucleotide PDE inhibitors might improve results by evoking a more restricted set of cellular responses.

Authors+Show Affiliations

Cardiology Division, University of Utah Health Sciences Center, 50 North Medical Drive, Salt Lake City, UT 84132, USA. matthew.movsesian@hsc.utah.edu.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

Language

eng

PubMed ID

11060720

Citation

Movsesian, M A.. "Therapeutic Potential of Cyclic Nucleotide Phosphodiesterase Inhibitors in Heart Failure." Expert Opinion On Investigational Drugs, vol. 9, no. 5, 2000, pp. 963-73.
Movsesian MA. Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure. Expert Opin Investig Drugs. 2000;9(5):963-73.
Movsesian, M. A. (2000). Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure. Expert Opinion On Investigational Drugs, 9(5), 963-73.
Movsesian MA. Therapeutic Potential of Cyclic Nucleotide Phosphodiesterase Inhibitors in Heart Failure. Expert Opin Investig Drugs. 2000;9(5):963-73. PubMed PMID: 11060720.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure. A1 - Movsesian,M A, PY - 2000/11/4/pubmed PY - 2001/2/28/medline PY - 2000/11/4/entrez SP - 963 EP - 73 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 9 IS - 5 N2 - There are several reasons to believe that agents that augment cAMP-mediated signalling in cardiac myocytes should have beneficial effects in patients with heart failure. However, clinical trials of first-generation cyclic nucleotide phosphodiesterase (PDE3) inhibitors, which raise cAMP content by blocking its hydrolysis, have shown that chronic administration of these drugs affect survival adversely. The problem may be the non-selective activation of a broad spectrum of cAMP-regulated cellular responses these agents elicit. More selective (or alternatively selective) cyclic nucleotide PDE inhibitors might improve results by evoking a more restricted set of cellular responses. SN - 1354-3784 UR - https://www.unboundmedicine.com/medline/citation/11060720/Therapeutic_potential_of_cyclic_nucleotide_phosphodiesterase_inhibitors_in_heart_failure_ L2 - https://www.tandfonline.com/doi/full/10.1517/13543784.9.5.963 DB - PRIME DP - Unbound Medicine ER -